We have previously identified the guaninerich oligonucleotide (ODN) 93del as a potent inhibitor in vitro of HIV-1 integrase. Moreover, low nanomolar concentrations of ODN 93del have been shown to inhibit HIV-1 replication in infected cells.
Methods
To investigate the ex vivo mechanism of ODN 93del inhibition, we analysed its antiviral effects on the early steps of HIV-1 replication such as viral entry, reverse transcription and integration using quantitative PCR.
Results
In addition to the effect on viral entry previously described for other guanine-quadruplex ODNs, transfection experiments showed that ODN 93del severely affects the proviral integration step independently of the effect on viral entry. Moreover, incubation of viral particles with ODN 93del revealed a potential microbicide activity of the aptamer.
Conclusions
Our data point to an original multimodal inhibition of HIV-1 replication by ODN 93del, strongly suggesting that targets of guanine-quartet-forming ODNs involve entry as well as other intracellular early steps of HIV-1 replication.
References
1.
Barré-SinoussiF., ChermannJ.C., ReyF.Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science1983; 220: 868–871.
2.
StolkL.M., LuersJ.F.Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci2004; 26: 133–136.
3.
ChunT.W., StuyverL., MizellS.B.Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A1997; 94: 13193–13197.
4.
ClavelF., HanceA.J.HIV drug resistance. N Engl J Med2004; 350: 1023–1035.
5.
MillerM.D., FarnetC.M., BushmanF.D.Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol1997; 71: 5382–5390.
6.
EmeryS., WinstonA.Raltegravir: a new choice in HIV and new chances for research. Lancet2009; 374: 764–766.
7.
BrodyE.N., GoldL.Aptamers as therapeutic and diagnostic agents. J Biotechnol2000; 74: 5–13.
8.
GoldL., BrownD., HeY., ShtatlandT., SingerB.S., WuY.From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc Natl Acad Sci U S A1997; 94: 59–64.
9.
SchneiderD.J., FeigonJ., HostomskyZ., GoldL.High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry1995; 34: 9599–9610.
10.
PileurF., AndreolaM.L., DausseE.Selective inhibitory DNA aptamers of the human RNase H1. Nucleic Acids Res2003; 31: 5776–5788.
11.
KenschO., ConnollyB.A., SteinhoffH.J., McGregorA., GoodyR.S., RestleT.HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem2000; 275: 18271–18278.
12.
DeStefanoJ.J., NairG.R.Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides2008; 18: 133–144.
13.
DeStefanoJ.J., CristofaroJ.V.Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res2006; 34: 130–139.
14.
JoshiP., PrasadV.R.Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol2002; 76: 6545–6557.
15.
TuerkC., MacDougal-WaughS.In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene1993; 137: 33–39.
16.
MarozziA., MeneveriR., GiaccaM., GutierrezM.I., SiccardiA.G., GinelliE.In vitro selection of HIV-1 TAR variants by the Tat protein. J Biotechnol1998; 61: 117–128.
17.
MétifotM., LeonO., Tarrago-LitvakL., LitvakS., AndreolaM.L.Targeting HIV-1 integrase with aptamers selected against the purified RNase H domain of HIV-1 RT. Biochimie2005; 87: 911–919.
18.
AllenP., WorlandS., GoldL.Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology1995; 209: 327–336.
19.
JingN., De ClercqE., RandoR.F.Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design. J Biol Chem2000; 275: 3421–3430.
20.
AndreolaM.L., PileurF., CalmelsC.DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry2001; 40: 10087–10094.
21.
PhanA.T., KuryavyiV., MaJ.B., FaureA., AndreolaM.L., PatelD.J.An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc Natl Acad Sci U S A2005; 102: 634–639.
22.
de SoultraitV.R., LozachP.Y., AltmeyerR., Tarrago-LitvakL., LitvakS., AndreolaM.L.DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol2002; 324: 195–203.
23.
OjwangJ.O., BuckheitR.W., PommierY.T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother1995; 39: 2426–2435.
24.
EstéJ.A., CabreraC., ScholsD.Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol1998; 53: 340–345.
25.
MétifotM., FaureA., Guyonnet-DuperatV.Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery?Oligonucleotides2007; 17: 151–165.
26.
CharneauP., MirambeauG., RouxP., PaulousS., BucH., ClavelF.HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol1994; 241: 651–662.
27.
VenturaM., Tarrago-LitvakL., DolleV.Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Arch Virol1999; 144: 513–523.
28.
BrusselA., MathezD., Broche-PierreS.Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS2003; 17: 645–652.
29.
BabaM., PauwelsR., BalzariniJ., ArnoutJ., DesmyterJ., De ClercqE.Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A1988; 85: 6132–6136.
30.
D'AndreaG., BrisdelliF., BozziA.AZT: an old drug with new perspectives. Curr Clin Pharmacol2008; 3: 20–37.
31.
SchultzeP., MacayaR.F., FeigonJ.Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol1994; 235: 1532–1547.
32.
DolléV., FanE., NguyenC.H.A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem1995; 38: 4679–4686.
33.
ReigadasS., AndreolaM.L., WittkopL.Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother2010; 65: 434–437.
34.
NeidleS.The structures of quadruplex nucleic acids and their drug complexes. Curr Opin Struct Biol2009; 19: 239–250.
35.
TanJ.H., GuL.Q., WuJ.Y.Design of selective G-quadruplex ligands as potential anticancer agents. Mini Rev Med Chem2008; 8: 1163–1178.
36.
PatelD.J., PhanA.T., KuryavyiV.Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res2007; 35: 7429–7455.
37.
WuY.The second chance story of HIV-1 DNA: unintegrated? Not a problem! Retrovirology2008; 5: 61.
38.
ZhuK., DobardC., ChowS.A.Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol2004; 78: 5045–5055.
39.
HehlE.A., JoshiP., KalpanaG.V., PrasadV.R.Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol2004; 78: 5056–5067.
40.
BuckheitR.W.Jr., WatsonK.M., MorrowK.M., HamA.S.Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res2010; 85: 142–158.
